肺癌中的表皮生长因子受体（EGRF）

Carcereny Enric, Morán Teresa, Capdevila Laia, Cros Sara, Vilà Laia, de Los Llanos Gil Maria, Remón Jordi, Rosell Rafael

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.

Hospital Santa Tecla, Tarragona, Spain.

Transl Respir Med. 2015 Feb 24;3:1. doi: 10.1186/s40247-015-0013-z. eCollection 2015.

In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.

在过去十年中，我们对癌症生物学的理解取得了重要进展，尤其是在非小细胞肺癌（NSCLC）方面，发现了该疾病的致癌驱动因素。表皮生长因子受体（EGFR）基因及其信号通路是首个被发现可在肺癌中发生突变并能进行治疗的致癌驱动因素。对于经分子筛选的EGFR突变患者，使用EGFR酪氨酸激酶抑制剂（TKIs）进行治疗是标准的治疗方案，而其在未经筛选的肺癌患者中的作用如今仍存在争议。本综述将概述EGFR信号通路及其在肺癌治疗中的选择。